Occlusive Stroke Clinical Trial
Official title:
Safety and Utility Profile of the Asahi Chikai Black 18 neuRovascular guidewirE in Large Vessel Occlusive Stroke: SURE 18 Registry
| NCT number | NCT03438565 |
| Other study ID # | GCO 17-2723 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | March 18, 2018 |
| Est. completion date | February 1, 2020 |
| Verified date | March 2020 |
| Source | Icahn School of Medicine at Mount Sinai |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
The objective of this study is to obtain post market data on the Asahi Chikai Black 18 neurovascular guidewire in the treatment of intracranial large vessel occlusive stroke. This will be compared to a historical control that will include the prior 50 consecutive patients fitting the same selection criteria.
| Status | Completed |
| Enrollment | 100 |
| Est. completion date | February 1, 2020 |
| Est. primary completion date | February 1, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Male or female patients presenting with acute anterior cerebral circulation large vessel occlusive stroke - ASPECT score 5 or better - Occlusion of the ICA terminus and M1 MCA - Favorable CT perfusion with clinical/radiologic mismatch - Last known well out to 24 hours - Age limit >18 years - Baseline mRS 0-3 Exclusion Criteria: - Intracranial hemorrhage - ASPECTS (Alberta stroke program early CT score) <5 - Unfavorable CT perfusion - Baseline mRS 4 or greater - Large vessel occlusive stroke with tandem lesion of the cervical internal carotid artery or posterior circulation |
| Country | Name | City | State |
|---|---|---|---|
| United States | Icahn School of Medicine at Mount Sinai | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Icahn School of Medicine at Mount Sinai | Asahi Intecc USA Inc |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Time to clot engagement | Time from guide catheter placement within the target ICA to clot engagement | 30 days | |
| Primary | Number of device related serious adverse events | Safety profile as measured by number of Intra-procedural device related serious adverse events | Day 1 | |
| Secondary | Modified Rankin Scale (mRS) | 0 No symptoms at all No significant disability despite symptoms; able to carry out all usual duties and activities Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Moderate disability; requiring some help, but able to walk without assistance Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance Severe disability; bedridden, incontinent and requiring constant nursing care and attention Dead |
90 days post procedure | |
| Secondary | Change in NIH Stroke Scale (NIHSS) | The score for each ability is a number between 0 (normal functioning) to 4 (completely impaired). The NIHSS has 11 different items and the highest possible score is 42. The higher the score, the more impaired a stroke patient is. | 24 hours | |
| Secondary | Number of neurovascular guidewires required per case | Day 1 |